No previous studies to date compared the effect of long acting GLP-1 receptor agonist liraglutide and selective PDE4 inhibitor roflumilast that is involved in GLP-1 release on body weight either in PCOS or any other obese population. Here, GCG is linked to polycystic ovary syndrome.